治疗帕金森病的疾病修改试验:"稳定治疗"不等于生物稳定性
M Maral Mouradian1, A Jon Stoessl2, Anthony E Lang3
1Robert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Health, Piscataway, New Jersey, USA.
概括
帕金森病的临床试验正在转变,包括服用药物的患者. 本综述强调了由于药物对大脑变化和结果的影响,解释结果的挑战.
科学领域:
- 神经学 神经学
- 临床试验设计 临床试验设计
- 药理学 药理学是指药理学的学科.
背景情况:
- 传统的帕金森病 (PD) 试验包括以前没有服用过药物的患者.
- 最近的试验将PD患者注册为稳定的抗帕金森药物.
- 目前的试验设计缺乏统一的药物治疗方案,并且无法考虑药理学变化.
研究的目的:
- 审查多巴胺疗法对帕金森病试验中的临床和神经成像结果的影响.
- 鉴定因药物效应而导致的试验结果解释方面的挑战.
主要方法:
- 对帕金森病中多巴胺类疗法研究的文献综述.
- 对药物对临床和神经成像结果措施的影响分析.
- 讨论解释试验结果的挑战.
主要成果:
- 多巴氨基疗法,特别是列沃多巴,会在帕金森患者的大脑中诱导显著的药学动力学变化.
- 这些药物诱导的变化可能会混临床和神经成像结果的解释.
- 缺乏标准化药物治疗方案使结果评估复杂化.
结论:
- 目前的试验设计招募药物治疗的帕金森病患者面临解释挑战.
- 了解药物效应对于准确评估疾病修饰疗法至关重要.
- 未来的试验设计必须考虑多巴胺疗法对结果的影响.
相关概念视频
Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
Parkinson's Disease: Overview
716
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
716
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Neural Regulation
40.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.3K
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Clinical Trials
8.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.6K


